In 2018, researchers at the Mayo Clinic published a study that sent shockwaves through the longevity community. They tested a panel of natural compounds for senolytic activity — the ability to selectively kill senescent “zombie” cells that accumulate with age and drive chronic disease. One compound stood above all others in potency and selectivity. It was not some exotic pharmaceutical. It was fisetin — a flavonoid found in strawberries, apples, persimmons, and onions.
In aged mice, a short course of high-dose fisetin reduced senescent cell burden across multiple tissues, decreased systemic inflammation, improved tissue function, and extended remaining lifespan by approximately 10%. Not in young mice given lifelong treatment. In old mice, given fisetin late in life. This was the biological equivalent of taking an elderly human and giving them back a decade of health.
The Enhanced Man does not wait for clinical trials to complete when the mechanism is clear, the safety profile is favorable, and the potential upside is this significant. Fisetin is the most accessible senolytic tool available today.
Understanding Senescent Cells: The Zombie Problem
Cellular senescence is a state where cells stop dividing but refuse to die. When a cell accumulates too much DNA damage, telomere shortening, or oncogenic stress, it enters this permanent growth arrest as a protection mechanism — stopping a potentially cancerous cell from replicating. In young organisms, the immune system efficiently clears these senescent cells. The problem arrives with aging.
As the immune system degrades (see our deep dive on Thymosin Alpha-1 and immune restoration), senescent cells accumulate. A healthy 20-year-old might have senescent cells comprising less than 1% of total cells. By 70, that number can exceed 15% in some tissues. And these cells are not passive bystanders.
Senescent cells secrete a toxic cocktail called the Senescence-Associated Secretory Phenotype (SASP) — a mixture of inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-8), matrix metalloproteinases (MMPs that degrade tissue structure), growth factors (that promote abnormal cell growth), and chemokines (that recruit more immune cells, creating chronic inflammation). The SASP spreads senescence to neighboring healthy cells through paracrine signaling — zombie cells creating more zombies.
This accumulation drives virtually every age-related disease: atherosclerosis (senescent endothelial cells and foam cells), osteoarthritis (senescent chondrocytes), pulmonary fibrosis (senescent lung epithelium), neurodegeneration (senescent glia and neurons), diabetes (senescent pancreatic beta cells), and cancer (SASP creates a pro-tumorigenic microenvironment).
For the full science of senolytics, read our comprehensive guide: Senolytics: How to Kill Zombie Cells Before They Kill You.
How Fisetin Works as a Senolytic
Senescent cells survive by upregulating anti-apoptotic survival pathways — essentially, they turn on cellular “stay alive” signals to resist the normal cell death processes. The key survival networks include the Bcl-2 family proteins, PI3K/AKT signaling, p53/p21/serpine pathways, and HIF-1α-dependent metabolic adaptations.
Fisetin acts as a senolytic by inhibiting multiple pro-survival pathways simultaneously:
PI3K/AKT/mTOR inhibition: Fisetin suppresses the PI3K/AKT pathway, which senescent cells depend on for survival. By blocking this pathway, senescent cells lose their resistance to apoptosis and die through normal programmed cell death.
Bcl-2 family modulation: Fisetin shifts the balance between pro-apoptotic (Bax, Bak) and anti-apoptotic (Bcl-2, Bcl-xL) proteins in senescent cells, tipping them toward death. Crucially, this effect is selective — healthy cells with normal Bcl-2 ratios are not significantly affected.
NF-κB suppression: Fisetin inhibits the NFκB inflammatory pathway that drives the SASP. This reduces the toxic secretions of senescent cells even before they die, providing anti-inflammatory benefit independent of the senolytic effect.
Oxidative stress induction in senescent cells: Fisetin can paradoxically increase oxidative stress specifically in senescent cells (which have compromised antioxidant defenses) while actually acting as an antioxidant in healthy cells. This differential effect is key to senolytic selectivity.
The Mayo Clinic Data
The pivotal 2018 study by Yousefzadeh et al. at Mayo Clinic tested 10 flavonoids for senolytic activity in multiple cell types. Fisetin was the most potent across all senescent cell types tested — including human adipose-derived mesenchymal stem cells, human umbilical vein endothelial cells, and mouse embryonic fibroblasts.
In aged mice (equivalent to approximately 75-80 human years), intermittent high-dose fisetin treatment reduced senescent cell markers (p16, p21, SA-β-gal) in multiple tissues, decreased inflammatory cytokines in the blood, and extended median remaining lifespan by approximately 10%. The treatment was given orally at a dose of 100mg/kg for 5 consecutive days, repeated monthly.
Importantly, fisetin showed no toxic effects at senolytic doses. No organ damage, no immune suppression, no adverse events. This is a critical advantage over pharmaceutical senolytics like the dasatinib + quercetin combination, which carries more significant side effect profiles.
Fisetin vs Dasatinib + Quercetin
The two leading senolytic protocols are fisetin (alone) and the dasatinib + quercetin (D+Q) combination. How do they compare?
Potency: D+Q is likely more potent per dose. Dasatinib is a powerful tyrosine kinase inhibitor that hits multiple senescent cell survival pathways aggressively. The D+Q combination has shown the most dramatic senolytic effects in animal studies and is the furthest along in human clinical trials.
Safety: Fisetin wins decisively. Dasatinib is a chemotherapy drug with meaningful side effects — gastrointestinal issues, fluid retention, fatigue, and potential hematological effects. Q+D requires more careful medical oversight. Fisetin is a naturally occurring dietary compound with an excellent safety profile even at high doses.
Accessibility: Fisetin is available as a dietary supplement, no prescription needed. Dasatinib requires a prescription and is expensive.
Evidence quality: D+Q has more advanced human clinical trial data (several Phase 1/2 trials completed). Fisetin human trials are underway at Mayo Clinic but results are pending.
For most Enhanced Athletes, fisetin is the rational first-line senolytic. Reserve D+Q for more aggressive protocols under medical supervision. Read our detailed senolytics guide for the full D+Q protocol.
The Fisetin Dosing Protocol
Senolytic Protocol (High-Dose Pulsed)
Based on allometric scaling from the mouse studies, the human senolytic dose is approximately 20mg/kg body weight — roughly 1,500mg for a 75kg person. The protocol:
Loading phase: 1,500-2,000mg fisetin daily for 2-3 consecutive days. Take with fat-containing meals — fisetin is lipophilic and fat dramatically improves absorption. Coconut oil, olive oil, or fish oil all work.
Frequency: Repeat the 2-3 day pulse once monthly. Senescent cells accumulate gradually, so monthly clearance is sufficient to prevent buildup.
Cycling: Run the monthly protocol for 3-6 months, then take 2-3 months off and reassess with bloodwork. This prevents any theoretical concern about chronic suppression of beneficial senescence (such as wound-healing-associated temporary senescence).
Daily Antioxidant/Anti-Inflammatory Protocol (Low-Dose)
For ongoing anti-inflammatory and neuroprotective benefits without the senolytic pulse: 100-500mg daily with food. This provides the NF-κB suppression, antioxidant, and neuroprotective benefits of fisetin without necessarily achieving full senolytic clearance. Many people run this continuously between senolytic pulses.
Bioavailability Enhancement
Fisetin has notoriously poor oral bioavailability. Strategies to maximize absorption:
Take with healthy fats (this is essential, not optional). Liposomal fisetin formulations show dramatically improved bioavailability. Fisetin combined with galactomannan fiber shows improved pharmacokinetics in preliminary studies. Avoid taking with large amounts of protein, which may compete for absorption.
Beyond Senolytics: Fisetin’s Other Benefits
Neuroprotection: Fisetin activates the ERK pathway and promotes the production of neurotrophic factors including BDNF. In animal models, it improves learning and memory in aged mice and reduces neuroinflammation. Fisetin also inhibits the aggregation of amyloid-beta and tau proteins — the pathological hallmarks of Alzheimer’s disease.
Anti-cancer effects: Through PI3K/AKT/mTOR inhibition, NF-κB suppression, and direct anti-proliferative effects, fisetin has shown anti-cancer activity in cell culture and animal models across multiple cancer types including prostate, breast, colon, and lung.
Insulin sensitization: Fisetin improves insulin sensitivity through AMPK activation and reduction of inflammatory signaling that drives insulin resistance.
Cardiovascular protection: Fisetin protects endothelial function, reduces oxidative damage to LDL cholesterol (preventing the oxidized LDL that drives atherosclerosis), and reduces vascular inflammation.
Monitoring and Bloodwork
Track the effectiveness of your senolytic protocol through the Enhanced Athlete Protocol bloodwork framework:
Inflammatory markers: hs-CRP, IL-6, TNF-α. These should decrease over 3-6 months of monthly senolytic pulsing as the SASP burden is reduced.
Metabolic markers: Fasting insulin, HbA1c, HOMA-IR. Improved insulin sensitivity indicates reduced senescent cell-mediated metabolic dysfunction.
Emerging biomarkers: GDF-15 (growth differentiation factor 15) is emerging as a senescence-associated biomarker. Elevated GDF-15 correlates with senescent cell burden, and effective senolytic treatment should reduce it.
Epigenetic clocks: DNA methylation-based biological age testing (GrimAge, DunedinPACE) can track whether senolytic protocols are actually decelerating biological aging rate. Test at baseline and after 6-12 months of protocol adherence.
The Bottom Line
Fisetin is the most accessible, safest, and most practical senolytic available today. It clears zombie cells, reduces systemic inflammation, protects the brain, improves metabolic function, and extended remaining lifespan by 10% in aged mice. And it comes from strawberries.
The irony is perfect. People will spend thousands on exotic interventions while ignoring a flavonoid that costs less than a dollar a day and addresses one of the fundamental mechanisms of aging. The Enhanced Man does not make this mistake. He identifies the highest-impact interventions, implements them systematically, and monitors the results.
Clear the zombies. Restore the tissue. Measure the outcome. This is the Enhanced Athlete Protocol approach to aging — systematic, measurable, and relentless.
For the complete longevity framework including peptides, supplements, and bloodwork monitoring, visit the Enhanced Athlete Protocol hub.